Your browser doesn't support javascript.
loading
Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting.
Carnero Contentti, Edgar; Lopez, Pablo A; Tkachuk, Verónica; Vrech, Carlos; Zarate, María A; Correale, Jorge; Deri, Norma; Luetic, Geraldine; Marrodan, Mariano; Pagani Cassara, Fátima; Tavolini, Darío; Ysrraelit, María Célica; Balbuena, María E; Hryb, Javier; Chiganer, Edson; Leguizamon, Felisa; Knorre, Eduardo; Zanga, Gisela; Pestchanker, Claudia; Barboza, Andrés; Nadur, Débora; Cristiano, Edgardo; Patrucco, Liliana; Alonso, Ricardo; Alonso Serena, Marina; Paul, Friedemann; Rojas, Juan Ignacio.
Afiliación
  • Carnero Contentti E; Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina.
  • Lopez PA; Neuroimmunology Unit, Department of Neurosciences, Hospital Alemán, Buenos Aires, Argentina.
  • Tkachuk V; Sección de Neuroinmunología y Enfermedades Desmielinizantes, Servicio de Neurología, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.
  • Vrech C; Departamento de Enfermedades Desmielinizantes, Sanatorio Allende, Córdoba, Argentina.
  • Zarate MA; Departamento de Enfermedades Desmielinizantes, Sanatorio Allende, Córdoba, Argentina.
  • Correale J; Departamento de Neurología, Fleni, Buenos Aires, Argentina.
  • Deri N; Centro de Especialidades Neurológicas y Rehabilitación, CENyR, Buenos Aires, Argentina.
  • Luetic G; Instituto de Neurociencias de Rosario, Rosario, Argentina.
  • Marrodan M; Departamento de Neurología, Fleni, Buenos Aires, Argentina.
  • Pagani Cassara F; Instituto de Neurociencias, Fundación Favaloro/INECO/Buenos Aires, Argentina Servicio de Neurología, Hospital Universitario Austral, Buenos Aires, Argentina.
  • Tavolini D; INECO Neurociencias Oroño, Rosario, Argentina.
  • Ysrraelit MC; Departamento de Neurología, Fleni, Buenos Aires, Argentina.
  • Balbuena ME; Sección de Neuroinmunología y Enfermedades Desmielinizantes, Servicio de Neurología, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.
  • Hryb J; Consultorio de Neuroinmunología, Hospital Carlos G. Durand, Buenos Aires, Argentina.
  • Chiganer E; Consultorio de Neuroinmunología, Hospital Carlos G. Durand, Buenos Aires, Argentina.
  • Leguizamon F; Hospital de Agudos, Dr. Teodoro Álvarez, Buenos Aires, Argentina.
  • Knorre E; Hospital de Agudos, Dr. Teodoro Álvarez, Buenos Aires, Argentina.
  • Zanga G; Departamento de Neurología, Hospital Cesar Milstein, Buenos Aires, Argentina.
  • Pestchanker C; Hospital Central Dr. Ramón Carrillo, San Luis, Argentina.
  • Barboza A; Hospital Central de Mendoza, Mendoza, Argentina.
  • Nadur D; Sección de Neuroinmunología y Enfermedades Desmielinizantes, Servicio de Neurología, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.
  • Cristiano E; Centro de Esclerosis Múltiple de Buenos Aires, Buenos Aires, Argentina.
  • Patrucco L; Centro de Esclerosis Múltiple de Buenos Aires, Buenos Aires, Argentina.
  • Alonso R; Centro Universitario de Esclerosis Múltiple, Hospital Ramos Mejía, Buenos Aires, Argentina.
  • Alonso Serena M; Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Paul F; NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Rojas JI; Freie Universität Berlin, Berlin, Germany.
Mult Scler ; 29(10): 1240-1249, 2023 09.
Article en En | MEDLINE | ID: mdl-37491849
ABSTRACT

BACKGROUND:

We aimed to assess the frequency of new asymptomatic lesions on brain and spinal imaging (magnetic resonance imaging (MRI)) and their association with subsequent relapses in a large cohort of neuromyelitis optica spectrum disorder (NMOSD) patients in Argentina.

METHODS:

We retrospectively reviewed 675 MRI (225 performed during an attack and 450 during the relapse-free period (performed at least 3 months from the last attack)) of NMOSD patients who had at least 2 years of clinical and MRI follow-up since disease onset. Kaplan-Meier (KM) curves were used for depicting time from remission MRI to subsequent relapse.

RESULTS:

We included 135 NMOSD patients (64.4% were aquaporin-4-immunoglobulin G (AQP4-IgG)-positive). We found that 26 (19.26%) and 66 (48.88%) of patients experienced at least one new asymptomatic MRI lesion during both the relapse-free period and attacks, respectively. The most frequent asymptomatic MRI lesions were optic nerves followed by short-segment myelitis during the relapse-free period and attacks. KM curves did not show differences in the time taken to develop a new relapse.

CONCLUSION:

Our findings showed that new asymptomatic lesions are relatively frequent. However, the presence of new asymptomatic MRI lesions during the relapse-free period and at relapses was not associated with a shorter time to developing subsequent relapses.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neuromielitis Óptica Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Argentina

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neuromielitis Óptica Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Argentina